Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

ÆæÅå½ÃÇʸ°ÀÌ ¹æ»ç¼± ºÐÇÒÁ¶»ç¿¡ ÀÇÇÑ ÁãÀÇ Ã´¼ö¼Õ»ó¿¡ ¹ÌÄ¡´Â ¿µÇâ The Effect of Pentoxifylline on Rat Spinal Cord Damage to Fractionated Irradiation

´ëÇѾÏÇÐȸÁö 1998³â 30±Ç 1È£ p.178 ~ 187
¼Ò¼Ó »ó¼¼Á¤º¸
±è¿øµ¿/Won Dong Kim

Abstract

¸ñÀû : ¹æ»ç¼±¿¡ ÀÇÇÑ Ã´¼öÀÇ ¼Õ»óÀº µå¹°±â´Â Çϳª Ä¡¸íÀûÀÌ°í ºÒ°¡¿ªÀûÀÎ ½É°¢ÇÑ ÇÕº´
ÁõÀÇ ÇϳªÀÌ´Ù. ÃÖ±Ù ÆæÅå½ÃÇʸ°(3,7-dimethyl-1(5-oxyhexyl)-xanthine)ÀÌ ÀϺΠ¹æ»ç¼± ¸¸¼º
ÈÄÀ¯Áõ(¿¬ºÎÁ¶Á÷ ±«»ç ¹× Æó¼Õ»ó)ÀÇ Ä¡·á ¹× ¿¹¹æ¿¡ È¿°ú°¡ ÀÖÀ½ÀÌ µ¿¹°½ÇÇèÀ» ÅëÇÏ¿© ¹àÇô
Áö°í ÀÖ´Ù. µû¶ó¼­ ÀúÀÚ´Â 7ÁÖµÈ Sprague-Dawley ratÀ» ´ë»óÀ¸·Î °í¿ë·®ÀÇ ÆæÅå½ÃÇʸ° °æ
±¸Åõ¿©°¡ ¹æ»ç¼± ºÐÇÒÁ¶»ç·Î ¾ß±âµÇ´Â ô¼ö¼Õ»ó¿¡ ¾î¶°ÇÑ ¿µÇâÀ» ¹ÌÄ¡´ÂÁö ¾Ë¾Æº¸°íÀÚ ÇÑ´Ù
Àç·á ¹× ¹æ¹ý : ÆæÅå½ÃÇʸ°À» ¸ê±ÕµÈ Áõ·ù¼ö¿¡ 2 g/LÀÇ ³óµµ·Î Èñ¼®ÇÏ¿© ¹æ»ç¼±Á¶»ç 1ÁÖÀü
ºÎÅÍ ¹æ»ç¼±Á¶»ç ÈÄ 40ÁÖ±îÁö ÁãµéÀÌ ÀÚÀ¯·Ó°Ô ¼·ÃëÇÏ°Ô Çϸç üÁß´ç ÀÏÀÏ Æò±Õº¹¿ë·® À»
°è»êÇÏ¿´´Ù. ¹æ»ç¼±Àº ºÐÇÒÁ¶»ç¹æ¹ý(2, 4, 8 ºÐÇÒ)¿¡ µû¶ó ´ëÁ¶±º¿¡¼­´Â 27¿¡¼­ 54 Gy±îÁö,
ÆæÅå½ÃÇʸ° Åõ¿©±º¿¡¼­´Â 30¿¡¼­ 59 Gy±îÁö Cl-T2 ôÃß ºÎÀ§¿¡ Á¶»çÇÏ¿´´Ù. Áã´Â °¢ ¹æ»ç
¼±·®¿¡ µû¶ó 6¸¶¸®¸¦ ¹èÁ¤ÇÏ°í ¹æ»ç¼±Á¶»ç ÈÄ 40ÁÖ±îÁö »óÁöÀÇ ¸¶ºñ¸¦ Æò°¡±âÁØÀ¸·Î »ï¾Æ
°üÂûÇÏ¿´´Ù. ÀÚ·áºÐ¼®Àº life-table method¸¦ »ç¿ëÇÏ¿´°í profit analysis¸¦ ÀÌ¿ëÇÏ¿© Áß¾Ó¹Ý
ÀÀ¼±·®(median response dose, ED50)°ú dose modification factor(DMF)¸¦ ±¸
ÇÏ¿´´Ù.
°á°ú : ¹æ»ç¼±Ä¡·á¸¸À» ¹ÞÀº 72¸¶¸®Áß 19¸¶¸®¿¡¼­, ÆæÅå½ÃÇʸ°À» Åõ¿© ¹ÞÀº 90¸¶¸®Áß 31¸¶
¸®¿¡¼­ »óÁö¸¶ºñ°¡ ¹æ»ç¼± Ä¡·á ÈÄ 4°³¿ù°ú 7°³¿ù »çÀÌ¿¡ ³ªÅ¸³µÀ¸¸ç Á¶Á÷ÇÐÀû °Ë»ç»ó ¾ç±º
¿¡¼­ ¸ðµÎ ¹éÁúºÎ ±«»ç Áï Á¶±â Áö¿¬ÇüÀÌ ÁÖµÈ ¼Ò°ßÀ¸·Î °üÂûµÇ¾ú´Ù. ºÐÇÒÁ¶»ç(2, 4,8ºÐÇÒ)¿¡
µû¸£´Â ED50ÀÇ °ªÀº ¹æ»ç¼±´Üµ¶Ä¡·á±º¿¡¼­ 37.2, 43.9, 53.2 Gy¿´À¸¸ç ÆæÅå½Ã
Çʸ°Åõ¿©±º¿¡¼­´Â 38.5, 47.5, 55.9 Gy¿´´Ù. À̷κÎÅÍ ±¸ÇÑ DMFÀÇ °ªÀº 1.03, 1.08, 1.05¿´À¸
¸ç Åë°èÇÐÀûÀÎ Àǹ̴ ¾ø¾ú´Ù.
°á·Ð : Á㸦 »ç¿ëÇÑ ¸ðµ¨¿¡¼­ °í¿ë·® ÆæÅå½ÃÇʸ°ÀÇ ¹æ»ç¼±¿¡ ´ëÇÑ Ã´¼öº¸È£ È¿°ú´Â ¹Ì¹Ì
ÇÏ¿´´Âµ¥ ±× ÀÌÀ¯´Â Á¶±â Áö¿¬Çü ¹éÁú±«»ç·Î ÀÎÇÑ Ã´¼ö¼Õ»óÀÌ ÁÖ¿´±â ¶§¹®ÀÌ´Ù. ¸¸±â Áö
¿¬Çü Ç÷°ü¼Õ»ó¿¡ ´ëÇÑ Á¤È®ÇÑ ÆæÅå½ÃÇʸ°ÀÇ È¿°ú¸¦ ¾Ë¾Æº¸±â À§ÇÏ¿©´Â ÁãÀÇ Æò±Õ¼ö¸íÀ»
°í·ÁÇÑ Á» ´õ ±ä ÃßÀû°üÂûÀÌ ÇÊ¿äÇÒ °ÍÀÌ´Ù.

Radiation myelopathy is a rare late complication that follows the curative radiotherapy.
But once a damage occurs, the injury leads not only to a significant irreversible
sequelae but also to a fatal condition and there is no specific measures to ameliorate the
damage. Thus the radiation myelopathy is the principal dose limiting factor that can
compromise local tumor control.
Presumedly two factors are involved in the late radiation injury in normal tissues. The
first is the depletion of parenchymal cells and the second is the vascular injury,
especially to endothelial cells, inducing functional changes through the impaired blood
flow. If the vascular theory is correct, a pharmacological approach to improve the blood
flow supply might be an effective means of preventing or treating the late radiation
injury. Recently, there is great interest in the potential value of pentoxyfylline(PTX) as
an inhibitor of normal tissue injury caused by radiation. The main action of PTX is to
improve tissue perfusion by increasing red blood cell deformity, inhibiting platelet
aggregation and stimulating prostacyclin release. Many promising early laboratory and
clinical investigations have already showed the possibility that PTX can be used to limit
the vascular disturbances and thus to reduce the late radiation damage(4¡­6). But until
now, there is no report about the PTX effect on the radiation myelopathy. In this study,
we select the rat spinal cord model to test the effectiveness of PTX. The specific aim is
to compare paresis in rat given PTX daily in the post irradiation period, with those
observed in control rat given placebo. If PTX is found effective in modifying radiation
myelopathy, it might be an effective means of preventing myelopathy, and could be a
useful tool for evaluating the mechanisms of radiation myelopathy because PTX could
work only on the vascular system.

Å°¿öµå

ÆæÅå½ÃÇʸ°; ¹æ»ç¼±; ô¼ö¼Õ»ó;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS